FUSN Fusion Pharmaceuticals Inc

Price (delayed)

$21.48

Market cap

$1.83B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$1.86B

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the ...

Highlights
FUSN's revenue has soared by 126% YoY
The gross profit has soared by 126% YoY
The quick ratio has declined by 29% since the previous quarter and by 16% year-on-year
Fusion Pharmaceuticals's debt has increased by 29% YoY and by 28% from the previous quarter

Key stats

What are the main financial stats of FUSN
Market
Shares outstanding
85.06M
Market cap
$1.83B
Enterprise value
$1.86B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.52
Price to sales (P/S)
882.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
913
Earnings
Revenue
$2.04M
EBIT
-$97.92M
EBITDA
-$93.51M
Free cash flow
-$87.67M
Per share
EPS
-$1.42
Free cash flow per share
-$1.05
Book value per share
$2.86
Revenue per share
$0.02
TBVPS
$3.87
Balance sheet
Total assets
$323.81M
Total liabilities
$81.98M
Debt
$64.55M
Equity
$241.83M
Working capital
$200.16M
Liquidity
Debt to equity
0.27
Current ratio
10.64
Quick ratio
10.21
Net debt/EBITDA
-0.38
Margins
EBITDA margin
-4,584%
Gross margin
100%
Net margin
-5,111.6%
Operating margin
-5,403.8%
Efficiency
Return on assets
-36.9%
Return on equity
-48.7%
Return on invested capital
-34.8%
Return on capital employed
-32.3%
Return on sales
-4,800%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FUSN stock price

How has the Fusion Pharmaceuticals stock price performed over time
Intraday
-0.09%
1 week
-0.14%
1 month
0.37%
1 year
399.53%
YTD
123.52%
QTD
0.75%

Financial performance

How have Fusion Pharmaceuticals's revenue and profit performed over time
Revenue
$2.04M
Gross profit
$2.04M
Operating income
-$110.24M
Net income
-$104.28M
Gross margin
100%
Net margin
-5,111.6%
FUSN's revenue has soared by 126% YoY
The gross profit has soared by 126% YoY
Fusion Pharmaceuticals's net margin has increased by 50% YoY but it has decreased by 11% from the previous quarter
Fusion Pharmaceuticals's operating margin has increased by 47% YoY but it has decreased by 13% from the previous quarter

Growth

What is Fusion Pharmaceuticals's growth rate over time

Valuation

What is Fusion Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.52
P/S
882.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
913
The EPS has grown by 29% YoY and by 2.1% from the previous quarter
The P/B is 128% higher than the last 4 quarters average of 3.3
Fusion Pharmaceuticals's equity has increased by 20% YoY and by 9% QoQ
FUSN's revenue has soared by 126% YoY
The P/S is 68% above the last 4 quarters average of 525.7

Efficiency

How efficient is Fusion Pharmaceuticals business performance
The ROS has soared by 52% YoY but it has contracted by 12% from the previous quarter
The return on invested capital has increased by 26% year-on-year
FUSN's ROA is down by 4.5% QoQ but it is up by 4.4% YoY
FUSN's return on equity is down by 4.5% since the previous quarter

Dividends

What is FUSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FUSN.

Financial health

How did Fusion Pharmaceuticals financials performed over time
Fusion Pharmaceuticals's total liabilities has increased by 29% from the previous quarter and by 25% YoY
Fusion Pharmaceuticals's current ratio has decreased by 29% from the previous quarter and by 16% YoY
Fusion Pharmaceuticals's debt is 73% less than its equity
Fusion Pharmaceuticals's debt has increased by 29% YoY and by 28% from the previous quarter
Fusion Pharmaceuticals's equity has increased by 20% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.